Objective To analyse the clinical and therapeutic conse-after the treatment was completed. The remaining two patients (three pyelo-ureteric systems) had persistently quences of bacillus Calmette-Guérin (BCG) perfusion therapy for carcinoma in situ (CIS) of the upper positive cytology. Of two patients who received BCG therapy through a ureteric catheter, one developed a urinary tract. Patients and methods Eight pyelo-ureteric systems in ureteric stricture and the other developed renal tuberculosis. five patients with cytologically confirmed CIS of the upper urinary tract were treated using perfusion of Conclusions Although long-term adaptation to a nephrostomy tube disturbs the quality of life of the BCG through a percutaneous nephrostomy tube in five and a retrograde ureteric catheter in three. Follow-patient, percutaneous perfusion therapy through a nephrostomy tube seems to be safer than retrograde up cystoscopy, retrograde pyelography and selective urinary cytology were obtained 4 weeks after the last perfusion through a ureteric catheter. Keywords Carcinoma in situ, bacillus Calmette-Guérin treatment and every 3 months thereafter. Results In three patients (five pyelo-ureteric systems) vaccine, upper urinary tract, percutaneous perfusion the cytology remained negative for 10-46 months and total cystectomy for CIS of the upper tract and

No abstract